Short-term Changes in hsCRP and NT-proBNP Levels in Hypertensive Emergencies

Abstract

Hypertension is associated with high cardiovascular risk. Both hsCRP and NT-proBNP also have been associated with elevated cardiovascular risk, at least in the long term. Much less is known about the short-term changes in these markers, for example, in hypertensive emergencies. In 59 consecutive patients with hypertensive emergencies, hsCRP and NT-proBNP were measured at baseline and at days 3–4 and 7–10 after admission. All patients with hsCRP levels above 10 mg/l during the study were excluded due to possible infections. We found elevated levels of hsCRP at baseline with a significant decline on days 3–4 (day 0: median 2.53 mg/l, days 3–4: median 1.65 mg/l [p<0.01 vs. baseline], days 7–10 median: 2.00 mg/l). Women had higher hsCRP levels than men, and patients with hypertensive cardiomyopathy by echocardiographic criteria had significantly higher hsCRP levels compared with patients without hypertensive cardiomyopathy throughout the study. NT-proBNP levels were clearly elevated at admission (median 158 ng/l) and declined highly significantly thereafter (day 3–4: 61 ng/l, p<0.0001 vs. baseline; day 7–10: 76 ng/l, p<0.0001 vs. baseline). Patients with hypertensive cardiomyopathy had higher NT-proBNP levels compared with those patients without. In hypertensive emergencies, NT-proBNP levels correspond to levels described in acute coronary syndrome and decline significantly under antihypertensive therapy. In addition, we found an acute decline in hsCRP in the short term after hypertensive emergencies. These data may have importance in the clinical setting of hypertensive emergencies and in the interpretation of epidemiological data.

hypertension - high-sensitive CRP - B-type natriuretic peptide

References

• 1 Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease.  N Engl J Med. 2001;  345 1291-1297
• 2 Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.  N Engl J Med. 1997;  336 973-979
• 3 Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.  Circulation. 1998;  98 731-733
• 4 Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men.  Circulation. 1999;  99 237-242
• 5 Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN. for the Val-HeFT Investigators . C-reactive protein in heart failure. Prognostic value and the effect of valsartan.  Circulation. 2005;  112 1428-1434
• 6 Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women.  Arterioscleros Thromb Vasc Biol. 2002;  22 1668-1673
• 7 Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and in-flammation in apparently healthy men.  Hypertension. 2001;  38 399-403
• 8 Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors.  Atherosclerosis. 2003;  167 73-79
• 9 Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events.  Circulation. 2003;  108 2993-2999
• 10 Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain.  Nature. 1988;  332 78-82
• 11 Wieczorek SJ, Wu AHB, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, Hager D, Gardetto N, Chiu A, Bailey KR, Maisel A. A rapid B-natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: A multicenter evaluation.  Am Heart J. 2002;  144 834-839
• 12 Heeschen C, Hamm CW, Mitrovic V, Lantelme N-H, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.  Circulation. 2004;  110 3206-3210
• 13 Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.  N Engl J Med. 2005;  352 666-675
• 14 Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment.  Clin Endocrinol. 1997;  47 287-296
• 15 Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching.  Endocrinology. 1993;  132 1961-1970
• 16 Troughton RW, Frampton CM, Yandie TG, Espiner EA, Nicholls MG, Richards MA. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.  Lancet. 2000;  355 1126-1130
• 17 Richards MA, Nicholls G, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.  Circulation. 2003;  107 2786-2792
• 18 März W, Tiran B, Seelhorst U, Wellnitz B, Bauersachs J, Winkelmann BR, Boehm BO. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen risk and cardiovascular health study.  Clin Chem. 2007;  53 1075-1083
• 19 Talwar S, Siebenhofer A, Williams B, Ng L. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction and plasma N terminal proBNP.  Heart. 2000;  83 278-282
• 20 Olsen MH, Wachtell K, Tuxen C, Fossum F, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.  J Hypertens. 2004;  22 1597-1604
• 21 Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, Kjeldsen SE, Devereux RB, Dahlöf B, Hildebrandt PR. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitive C-reactive protein in hypertension: a LIFE substudy.  J Hypertens. 2006;  24 1531-1539
• 22 Hoffmann R. für die Arbeitsgruppe Kardiovaskulärer Ultraschall der DGK . Positionspapier zu Qualitätsstandards in der Echokardiographie.  Z Kardiol. 2004;  93 975-986
• 23 Voelker W. für die Arbeitsgruppe Kardiovaskulärer Ultraschall der DGK . Strukturierter Datensatz zur Befunddokumentation in der Echokardiographie-Version 2004.  Z Kardiol. 2004;  93 987-1004
• 24 Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon  III  RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith  Jr  SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.  Circulation. 2003;  107 499-511
• 25 Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, Robbins DC, Howard BV, Devereux RB. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes.  Diabetes Care. 2003;  26 2664-2769
• 26 Somma S Di, Magrini L, Mazzone M, DeLeva R, Tabacco F, Marino R, Talucci V, Ferri E, Forte P, Cardelli P, Gentiloni N, Pittoni V. Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure.  Am J Emerg Med. 2007;  25 335-339
• 27 Ndrepepa G, Braun S, Niemöller K, Mehilli J, Beckerath N von, Beckerath O von, Vogt W, Schömig A, Kastrati A. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina.  Circulation. 2005;  112 2102-2107
• 28 Lemos JA De, Morrow DA, Bentley JH, Omland T, Sabatine MS, MacCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of the B-type natriuretic peptide in patients with acute coronary syndromes.  N Engl J Med. 2001;  345 1014-1021

Correspondence